Myomo (NYSEAMERICAN:MYO - Get Free Report) had its price objective upped by stock analysts at Craig Hallum from $9.00 to $11.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. Craig Hallum's price target suggests a potential upside of 87.81% from the stock's previous close.
A number of other equities analysts also recently commented on MYO. HC Wainwright restated a "buy" rating and issued a $7.50 target price on shares of Myomo in a research note on Wednesday, November 13th. Ascendiant Capital Markets increased their target price on Myomo from $8.50 to $9.00 and gave the stock a "buy" rating in a research report on Tuesday, November 12th.
Check Out Our Latest Report on Myomo
Myomo Stock Performance
Shares of NYSEAMERICAN MYO opened at $5.86 on Tuesday. Myomo has a 52-week low of $2.51 and a 52-week high of $7.17. The company has a market cap of $177.17 million, a price-to-earnings ratio of -24.74 and a beta of 1.68.
Hedge Funds Weigh In On Myomo
A number of institutional investors and hedge funds have recently bought and sold shares of MYO. GSA Capital Partners LLP boosted its holdings in shares of Myomo by 60.8% in the third quarter. GSA Capital Partners LLP now owns 103,342 shares of the company's stock valued at $414,000 after acquiring an additional 39,085 shares in the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Myomo in the 3rd quarter worth $401,000. Jane Street Group LLC acquired a new stake in shares of Myomo in the third quarter valued at $65,000. XTX Topco Ltd bought a new position in Myomo during the third quarter valued at about $149,000. Finally, Barclays PLC acquired a new stake in Myomo in the 3rd quarter valued at about $36,000. Institutional investors own 44.99% of the company's stock.
Myomo Company Profile
(
Get Free Report)
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Myomo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Myomo wasn't on the list.
While Myomo currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
